IL316091A - Compositions and methods for treating polymyalgia rheumatica by administering an IL-6R antagonist - Google Patents
Compositions and methods for treating polymyalgia rheumatica by administering an IL-6R antagonistInfo
- Publication number
- IL316091A IL316091A IL316091A IL31609124A IL316091A IL 316091 A IL316091 A IL 316091A IL 316091 A IL316091 A IL 316091A IL 31609124 A IL31609124 A IL 31609124A IL 316091 A IL316091 A IL 316091A
- Authority
- IL
- Israel
- Prior art keywords
- antagonist
- administering
- compositions
- methods
- polymyalgia rheumatica
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263327850P | 2022-04-06 | 2022-04-06 | |
| US202263350761P | 2022-06-09 | 2022-06-09 | |
| US202263389317P | 2022-07-14 | 2022-07-14 | |
| US202263424035P | 2022-11-09 | 2022-11-09 | |
| US202263424627P | 2022-11-11 | 2022-11-11 | |
| US202363445329P | 2023-02-14 | 2023-02-14 | |
| US202363445331P | 2023-02-14 | 2023-02-14 | |
| US202363447796P | 2023-02-23 | 2023-02-23 | |
| PCT/US2023/065361 WO2023196838A1 (en) | 2022-04-06 | 2023-04-05 | Compositions and methods for treating polymyalgia rheumatica by administering an il‑6r antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316091A true IL316091A (en) | 2024-12-01 |
Family
ID=86424726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316091A IL316091A (en) | 2022-04-06 | 2023-04-05 | Compositions and methods for treating polymyalgia rheumatica by administering an IL-6R antagonist |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230399410A1 (https=) |
| EP (1) | EP4504788A1 (https=) |
| JP (2) | JP7630012B2 (https=) |
| KR (1) | KR20240164816A (https=) |
| CN (1) | CN120569404A (https=) |
| AU (1) | AU2023250653A1 (https=) |
| CA (1) | CA3247400A1 (https=) |
| IL (1) | IL316091A (https=) |
| MX (1) | MX2024012345A (https=) |
| TW (1) | TW202405014A (https=) |
| WO (1) | WO2023196838A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025149845A1 (en) * | 2024-01-12 | 2025-07-17 | Sanofi Biotechnology | Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid |
| WO2025149846A1 (en) * | 2024-01-12 | 2025-07-17 | Sanofi Biotechnology | Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2398076T3 (es) * | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| WO2017106312A1 (en) * | 2015-12-18 | 2017-06-22 | Drexel University | Methods of modulating levels of il-6 and pd-l1 |
| EP3980459A1 (en) * | 2019-06-04 | 2022-04-13 | Sanofi Biotechnology | Compositions and methods for treating pain in subj ects with rheumatoid arthritis |
-
2023
- 2023-04-05 WO PCT/US2023/065361 patent/WO2023196838A1/en not_active Ceased
- 2023-04-05 IL IL316091A patent/IL316091A/en unknown
- 2023-04-05 CA CA3247400A patent/CA3247400A1/en active Pending
- 2023-04-05 AU AU2023250653A patent/AU2023250653A1/en active Pending
- 2023-04-05 EP EP23725056.8A patent/EP4504788A1/en active Pending
- 2023-04-05 CN CN202380041466.3A patent/CN120569404A/zh active Pending
- 2023-04-05 KR KR1020247036724A patent/KR20240164816A/ko active Pending
- 2023-04-05 US US18/130,980 patent/US20230399410A1/en active Pending
- 2023-04-05 JP JP2023560003A patent/JP7630012B2/ja active Active
- 2023-04-06 TW TW112112946A patent/TW202405014A/zh unknown
-
2024
- 2024-10-04 MX MX2024012345A patent/MX2024012345A/es unknown
-
2025
- 2025-01-31 JP JP2025014698A patent/JP2025072440A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024012345A (es) | 2024-11-08 |
| JP2025072440A (ja) | 2025-05-09 |
| TW202405014A (zh) | 2024-02-01 |
| US20230399410A1 (en) | 2023-12-14 |
| WO2023196838A1 (en) | 2023-10-12 |
| AU2023250653A1 (en) | 2024-11-21 |
| KR20240164816A (ko) | 2024-11-20 |
| EP4504788A1 (en) | 2025-02-12 |
| JP2024526414A (ja) | 2024-07-18 |
| CA3247400A1 (en) | 2023-10-12 |
| JP7630012B2 (ja) | 2025-02-14 |
| CN120569404A (zh) | 2025-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL316091A (en) | Compositions and methods for treating polymyalgia rheumatica by administering an IL-6R antagonist | |
| EP3917620A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS | |
| EP4292588A3 (en) | Administration of deuterated cftr potentiators | |
| MX2021010870A (es) | Bloqueadores de canales ionicos cargados y metodos de uso. | |
| MX2022005335A (es) | Bloqueadores de canales ionicos cargados y metodos de uso. | |
| IL309296A (en) | Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-) | |
| IL294066A (en) | Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist | |
| IL289731A (en) | Methods for treating or preventing asthma by administering an antagonist to il-4r | |
| IL316907A (en) | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS | |
| IL320362A (en) | Methods for treating hand and foot skin infections by administering an IL-4R antagonist | |
| HK40124116A (en) | Compositions and methods for treating polymyalgia rheumatica by administering an il-6r antagonist | |
| IL312187A (en) | Methods for treating prurigo nodularis by administering an IL-4R antagonist | |
| IL318016A (en) | Methods for treating eosinophilic esophagitis in children by administering an IL-4R antagonist | |
| IL316843A (en) | Compounds and methods for inhibiting SNCA deactivation | |
| CA3266767A1 (en) | ADVANCED COMPOSITIONS AND TREATMENT METHODS FOR SOLID TUMORS | |
| HK40110609A (en) | Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist | |
| HK40114753A (en) | Methods for treating prurigo nodularis by administering an il-4r antagonist | |
| CA3285901A1 (en) | Microbiota compositions and methods for treating disorders | |
| HK40111177A (en) | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder | |
| HK40084664A (en) | Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist | |
| AU2023900704A0 (en) | Microbiota Compositions and Methods for Treating Disorders | |
| IL326321A (en) | Methods and compositions for treating CTNNB1-related disorders | |
| CA3297601A1 (en) | Methods and compositions for treating ctnnb1-associated disorders | |
| IL321862A (en) | Methods and compounds for treating disorders caused by HSD-1 | |
| HK40120097A (en) | Methods for treating pediatric eosinophilic esophagitis by administering an il-4r antagonist |